Radiation induces an antitumour immune response to mouse melanoma

References

• Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N. 1998. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. The Journal of Experimental Medicine 188(7):1359–1368.
   PubMedGoogle Scholar
• Ang KK, Peters LJ, Weber RS, Morrison WH, Frankenthaler, RA, Garden AS, Goepfert H, Ha CS, Byers, RM. 1994. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. International Journal of Radiation Oncology, Biology & Physics 30(4):795–798.
   PubMedGoogle Scholar
• Ansari R, Gaber MW, Wang B, Pattillo CB, Miyamoto C, Kiani MF. 2007. Anti-TNFA (TNF-alpha) treatment abrogates radiation-induced changes in vacular density and tissue oxygenation. Radiation Research 167(1):80–86.
   PubMedGoogle Scholar
• Brown JM, Attardi LD. 2005. The role of apoptosis in cancer development and treatment response. National Review of Cancer 5(3):231–237.
   PubMedGoogle Scholar
• Cao ZA, Daniel D, Hanahan D. 2002. Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer 2:11.
   PubMed Web of Science ®Google Scholar
• Chang BK, Timmerman RD. 2007. Stereotactic body radiation therapy: a comprehensive review. American Journal of Clinical Oncology 30(6):637–644.
   PubMedGoogle Scholar
• Chiang CS, Hong JH, Wu YC, McBride WH, Dougherty GJ. 2000. Combining radiation therapy with interleukin-3 gene immunotherapy. Cancer Gene Therapy 7(18):1172–1178.
   PubMedGoogle Scholar
• Clarke C, Smyth MJ. 2007. Calreticulin exposure increases cancer immunogenicity. Nature Biotechnology 25(2):192–193.
   PubMedGoogle Scholar
• Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. 2004. Ionising radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. International Journal of Radiation Oncology, Biology & Physics 58(3):862–870.
   PubMedGoogle Scholar
• Fonseca C, Dranoff G. 2008. Capitalizing on the immunogenicity of dying tumor cells. Clinical Cancer Research 14(6):1603–1608.
   PubMedGoogle Scholar
• Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H, Hallahan DE. 2001. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Research 61(6):2413–2419.
   PubMed Web of Science ®Google Scholar
• Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN, Toledano A, Hellman S, Kufe DW, Weichselbaum RR. 1995. Spatial and temporal control of gene therapy using ionizing radiation. Nature Medicine 1(8):786–791.
   PubMedGoogle Scholar
• Hofbauer GF, Baur T, Bonnet MC, Tartour E, Burg G, Berinstein NL, Dummer R. 2008. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: The transgene determines the composition of the inflammatory infiltrate. Melanoma Research 18(2):104–111.
   PubMedGoogle Scholar
• Idoyaga J, Suda N, Suda K, Park CG, Steinman RM. 2009. Antibody to Langerin/CD207 localizes large numbers of CD8alpha+ dendritic cells to the marginal zone of mouse spleen. Proceedings of the National Academy of Sciences of the United States of America 106(5):1524–1529.
   PubMedGoogle Scholar
• Johansen P, Storni T, Rettig L, Qiu Z, Der-Sarkissian A, Smith KA, Manolova V, Lang KS, Senti G, Müllhaupt B, Gerlach T, Speck RF, Bot A, Kündig TM. 2008. Antigen kinetics determines immune reactivity. Proceedings of the National Academy of Sciences of the United States of America 105(13):5189–5194.
   PubMedGoogle Scholar
• Kaminski JM, Shinohara E, Summers JB, Niermann KJ, Morimoto A, Brousal J. 2005. The controversial abscopal effect. Cancer Treatment Reviews 31(13):159–172.
   PubMedGoogle Scholar
• Link BK, Ballas ZK, Weisdorf D, Wooldridge JE, Bassler AD, Shannon M, Rosmussen WL, Krieg AM, Weiner GJ. 2006. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. Journal of Immunotherapy 29(5):558–568.
   PubMedGoogle Scholar
• Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. 2005. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. The Journal of Immunology 174(12):7516–7523.
   PubMedGoogle Scholar
• Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. 2008. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. The Journal of Immunology 180(5):3132–3139.
   PubMedGoogle Scholar
• Majer M, Samlowski WE. 2007. Management of metastatic melanoma patients with brain metastases. Current Oncology Reports 9(5):411–416.
   PubMedGoogle Scholar
• Mason KA, Ariga H, Neal R, Valdecanos D, Hunter N, Krieg AM, Whisnant JK, Milas L. 2005. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clinical Cancer Research 11(1):361–369.
   PubMedGoogle Scholar
• Milas L, Mason KA, Ariga H, Hunter N, Neal R, Valdecanas D, Krieg AM, Whisnant JK. 2004. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Research 64(15):5074–5077.
   PubMed Web of Science ®Google Scholar
• Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, Zitvogel L, Kroemer G. 2007a. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death & Differentiation 14(10):1848–1850.
   PubMedGoogle Scholar
• Overgaard J, Overgaard M, Hansen PV, von der Maase H. 1986. Some factors of importance in the radiation treatment of malignant melanoma. Radiotherapy & Oncology 5(3):183–192.
   PubMedGoogle Scholar
• Overgaard J, von der Maase H, Overgaard M. 1985. A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. International Journal of Radiation Oncology, Biology & Physics 11(10):1837–1839.
   PubMedGoogle Scholar
• Parmiani G, Castelli C, Santinami M, Rivoltini L. 2007. Melanoma immunology: Past, present and future. Current Opinion in Oncology 19(2):121–127.
   PubMedGoogle Scholar
• Salama JK, Chmura SJ, Mehta N, Yenice KM, Stadler WM, Vokes EE, Hafaf DJ, Hellman S, Weichselbaum RR. 2008. An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clinical Cancer Research 14(16):5255–5259.
   PubMedGoogle Scholar
• Schoenborn JR, Wilson CB. 2007. Regulation of interferon-gamma during innate and adaptive immune responses. Advanced Immunology 96:41–101.
   PubMed Web of Science ®Google Scholar
• Somosy Z. 2000. Radiation response of cell organelles. Micron 31(2):165–181.
   PubMedGoogle Scholar
• Stevens G, McKay MJ. 2006. Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma. Lancet Oncology 7(7):575–583.
   PubMedGoogle Scholar
• Terando AM Faries MB, Morton DL. 2007. Vaccine therapy for melanoma: Current status and future directions. Vaccine 25(Suppl. 2):B4–16.
   PubMed Web of Science ®Google Scholar
• Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. 2008. Molecular characteristics of immunogenic cancer cell death. Cell Death & Differentiation 15(1):3–12.
   PubMedGoogle Scholar
• Yang G, Wu L, Chen L, Pei B, Wang Y, Zhan F, Wu Y, Yu Z. 2007. Targeted irradiation of shoot apical meristem of Arabidopsis embryos induces long-distance bystander/abscopal effects. Radiation Research 167(3):298–305.
   PubMedGoogle Scholar